Trade

with

Biomarin Pharmaceutical Inc
(NASDAQ: BMRN)
AdChoices
71.00
+0.55
+0.78%
After Hours :
71.00
0.00
0.00%

Open

70.39

Previous Close

70.45

Volume (Avg)

855.84k (1.12M)

Day's Range

70.10-71.76

52Wk Range

55.04-84.25

Market Cap.

10.45B

Dividend Rate ( Yield )

-

Beta

0.97

Shares Outstanding

147.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 548.48M

    • Net Income

    • -176.35M

    • Market Cap.

    • 10.45B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -29.76

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.97

    • Forward P/E

    • -97.09

    • Price/Sales

    • 16.26

    • Price/Book Value

    • 7.14

    • Price/Cash flow

    • -169.49

      • EBITDA

      • -118.79M

      • Return on Capital %

      • -9.46

      • Return on Equity %

      • -13.72

      • Return on Assets %

      • -9.46

      • Book Value/Share

      • 9.94

      • Shares Outstanding

      • 147.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 77.33

        • Credit Rating

        • BBB+

        • Analysts

        • 6

        • EPS Estimate

        • -1.04

        • Cashflow Estimate

        • -0.35

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 40.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 13.09

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 82.98

            • 82.75

            • Pre-Tax Margin

            • -27.75

            • 39.38

            • Net Profit Margin

            • -29.76

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 81.20

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -14.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -2.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.45

              • 0.76

              • Current Ratio

              • 7.32

              • 2.92

              • Quick Ratio

              • 5.75

              • 2.35

              • Interest Coverage

              • -5.58

              • 38.02

              • Leverage Ratio

              • 1.60

              • 2.21

              • Book Value/Share

              • 9.94

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -54.05

                • 238.10

                • P/E Ratio 5-Year High

                • -64.75

                • 634.30

                • P/E Ratio 5-Year Low

                • -11.69

                • 124.82

                • Price/Sales Ratio

                • 16.13

                • 8.94

                • Price/Book Value

                • 7.09

                • 8.12

                • Price/Cash Flow Ratio

                • -169.49

                • 47.85

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -13.72

                        (0.90)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -9.46

                        (-0.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -9.31

                        (-1.30)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 0.64

                      • 1.48

                      • Asset Turnover

                      • 0.32

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -156.01M
                      Operating Margin
                      -28.44
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -169.49
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      52.80%

                      Mutual Fund Ownership

                      59.59%

                      Float

                      87.88%

                      5% / Insider Ownership

                      0.91%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • VA CollegeAmerica Growth Fund of America

                      •  

                        7,339,073

                      • 3.14

                      • 4.99

                      • VA CollegeAmerica AMCAP

                      •  

                        5,748,861

                      • 9.40

                      • 3.91

                      • Vanguard Capital Opportunity Fund

                      •  

                        4,769,100

                      • 0.00

                      • 3.24

                      • Vanguard Mid-Cap Index Fund

                      •  

                        2,516,851

                      • 1.92

                      • 1.71

                      • Vanguard Total Stock Mkt Idx

                      •  

                        2,390,376

                      • 0.95

                      • 1.62

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        2,328,644

                      • 0.00

                      • 1.58

                      • Fidelity® OTC Portfolio

                      •  

                        2,266,956

                      • 0.00

                      • 1.54

                      • iShares Nasdaq Biotechnology

                      •  

                        1,964,800

                      • 3.08

                      • 1.30

                      • Prudential Jennison Health Sciences

                      •  

                        1,752,708

                      • 0.00

                      • 1.19

                      • VA CollegeAmerica New Economy

                      •  

                        1,752,550

                      • 9.81

                      • 1.19

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Capital Research Global Investors

                      •  

                        17,876,013

                      • +0.55%

                      • 12.15

                      • Sands Capital Management, LLC

                      •  

                        11,925,248

                      • +22.47%

                      • 8.11

                      • Fidelity Management and Research Company

                      •  

                        8,262,792

                      • +31.43%

                      • 5.62

                      • Vanguard Group, Inc.

                      •  

                        8,226,701

                      • +2.44%

                      • 5.59

                      • PRIMECAP Management Company

                      •  

                        8,064,219

                      • -1.22%

                      • 5.48

                      • Jennison Associates LLC

                      •  

                        5,347,735

                      • -33.32%

                      • 3.64

                      • State Street Corp

                      •  

                        4,318,081

                      • +10.95%

                      • 2.94

                      • BlackRock Fund Advisors

                      •  

                        3,915,314

                      • +1.30%

                      • 2.66

                      • Wells Capital Management Inc.

                      •  

                        2,477,831

                      • -16.62%

                      • 1.68

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Mid Growth

                      Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product ...morecandidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, a...moren enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.lessless

                      Key People

                      Jean-Jacques Bienaime

                      CEO/Director

                      Pierre Lapalme

                      Chairman of the Board/Director

                      Mr. Daniel K. Spiegelman

                      CFO/Executive VP

                      Dr. Robert A. Baffi,PhD

                      Executive VP, Divisional

                      Jeff Ajer

                      Other Corporate Officer/Executive VP

                      • Biomarin Pharmaceutical Inc

                      • 770 Lindaro Street

                      • San Rafael, CA 94901

                      • USA.Map

                      • Phone: +1 415 506-6700

                      • Fax: +1 415 382-7889

                      • bmrn.com

                      Incorporated

                      1996

                      Employees

                      1,341

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: